<DOC>
	<DOCNO>NCT00630695</DOCNO>
	<brief_summary>Injection day surgery 90 mg Lanreotide LP sub-cutaneously placebo . Evaluation lymphorrhea 2 arm study</brief_summary>
	<brief_title>Prevention Lymphorrhea Lanreotide Axillary Dissection Breast Cancer</brief_title>
	<detailed_description>Patients recruit among patient refer department breast cancer need axillary dissection . Enrolled patient injection Lanreotide placebo day surgery arrive room . The quantity lymph axillary drain daily note day 4 . The patient evaluate D15 , D30 M6 pain , lymphocele adverse event . Data compare 2 group .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Lymphocele</mesh_term>
	<mesh_term>Lanreotide</mesh_term>
	<mesh_term>Angiopeptin</mesh_term>
	<mesh_term>Somatostatin</mesh_term>
	<criteria>Adult patient ( &gt; 18 year ) , Patient undergo axillary lymphadenectomy breast cancer Patient give agreement inform Patients n't understand trial Type 2 diabetic patient Cyclosporine treatment Biliary lithiasis Pregnancy breast feed Allergic reaction Lanr√©otide class treatment Patient include another trial within last 30 day</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>Axillary lymphocele breast cancer</keyword>
</DOC>